🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11 results for “Vyvgart” Clear

  1. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. Placebo for efgartigimod, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  4. Placebo matching IMP., Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  5. Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  6. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  7. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  8. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  10. placebo PH20 SC PFS, Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  11. Vyvgart 20 mg/mL concentrate for solution for infusion

    The George Institute

    Patients affected by generalized myasthenia gravis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources